US fibrosis-focused drug developer Mediar Therapeutics has entered into global licensing agreement with US pharma major Eli ...

Mediar Therapeutics has entered a global licensing agreement with Eli Lilly and Company to progress the human immunoglobulin ...

Eli Lilly (NYSE:LLY) has entered into a licensing agreement with Mediar Therapeutics to advance Mediar's drug MTX-463 into ...

A Phase 2 trial of MTX-463 in idiopathic pulmonary fibrosis expected in 1H 2025.

Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...

Boston-area startup Mediar Therapeutics is teaming up with Eli Lilly on a new drug for idiopathic pulmonary fibrosis. Lilly — ...

Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...

(Nasdaq: IINN) (Nasdaq: IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, announced today that it is preparing for a potential production ramp-up of its INSPIRA™ ...

Cincinnati Bengals wide receiver Tee Higgins has stepped into the injury limelight once again. This time, it’s a knee injury for Higgins as his Bengals get ready to take on the Cleveland Browns in ...

A peptide called TCMCB07 will be administered to patients who are diagnosed with stage 4 metastatic colorectal cancer and will undergo chemotherapy. NORTHBROOK, Ill., Dec. 20, 2024 /PRNewswire/ -- ...

(KRON) — A 6-year-old boy who ran onto Interstate 280 in San Jose on Friday night was struck and killed by a passing vehicle, according to the California Highway Patrol. On Monday, the Santa ...